Clinical Trials Cosmetics Generic Drugs Licensing 
XTalks
FEBRUARY 8, 2021
In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world.
XTalks
AUGUST 2, 2023
AbbVie has also had some approvals made for their drugs, such as the European Commission approval of Skyrizi (risankizumab) and another FDA approval of Vraylar (cariprazine) , which marks the fourth indication for Vraylar, this time as an adjunctive therapy to antidepressants for major depressive disorder. billion in 2022. billion ($3.65
Expert insights. Personalized for you.
78 
Let's personalize your content